Acute Myeloid Leukemia Clinical Trial

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Summary

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drugs, such as venetoclax, busulfan, cladribine, and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax to the current standard of care stem cell transplant regimen of busulfan, fludarabine, and cladribine may help to control high-risk acute myeloid leukemia or myelodysplastic syndrome.

View Full Description

Full Description

Phase 2 Portion

Primary Objective 1) To obtain preliminary evidence of efficacy as defined by 1-year progression free survival.

Secondary Objectives

To determine:

Safety of this regimen as per NCI toxicity criteria
Time to neutrophil and platelet engraftment
Incidence of acute and chronic GVHD
Relapse incidence
Non-relapse mortality
Overall survival
Graft versus host disease-relapse free survival (GRFS)

Phase 3 Portion

Primary Objective

1) To compare progression free survival between two arms Arm 1 Standard of Care: fludarabine + IV busulfan (FluBu) versus Arm 2 Experimental: Venetoclax + Fractionated busulfan, cladribine, and fludarabine

Secondary Objectives To compare following between two arms

Safety of this regimen as per NCI toxicity criteria
Time to neutrophil and platelet engraftment
Incidence of acute and chronic GVHD
Relapse incidence
Non-relapse mortality
Overall survival
Graft versus host disease-relapse free survival (GRFS)

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Phase II

Age ≥ 18 and ≤ 70 years. English and non-English speaking participants are eligible.

Participants with acute myeloid leukemia who have previously received induction therapy and one of the following high-risk features:

ELN17 adverse risk prognostic group irrespective of remission status (see Appendix 2).
Measurable residual disease positive (MRD +)
Not in complete remission including complete remission without count recovery (Cri) and/or morphologic leukemia free state (MLFS), primary refractory, or relapsed disease. See Appendix 3 for details.
AML secondary to MDS or MPD
Therapy-related AML.
Not in complete remission after one course of induction therapy Or

Participants with myelodysplastic syndrome or CMML and one of the following high-risk features:

Poor or Very poor cytogenetic risk group as per IPSS-R
Mutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN1) or DNMT 3a or ASXL1 or RUNX1
Maximum IPSS-R >3.5 between diagnosis and the start of the preparative regimen.
≥ 5% BM blasts at transplant
Therapy-related MDS
HLA-identical sibling or a minimum of 7/8 matched unrelated donor, or a haploidentical related donor available
Participants must voluntarily sign an informed consent
Female participants of childbearing potential must have negative results for pregnancy test

Adequate hepatic and renal function per local laboratory reference range as follows:

Aspartate transaminase (AST) and alanine transaminase (ALT) < 3.0X ULN
Bilirubin <1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
Participants must have adequate renal function as demonstrated by a creatinine clearance ≥ 50 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.

Phase III

Age ≥ 18 and ≤ 65 years. English and non-English speaking participants are eligible.

Participants with acute myeloid leukemia who have previously received induction therapy and one of the following high-risk features:

ELN22 adverse risk prognostic group irrespective of remission status (see Appendix 3).
Measurable residual disease positive (MRD +)
Not in complete remission including complete remission without count recovery (Cri) and/or morphologic leukemia free state (MLFS), primary refractory, or relapsed disease. See Appendix 4 for details.
AML secondary to MDS or MPD
Therapy-related AML.
Not in complete remission after one course of induction therapy Or

Participants with myelodysplastic syndrome or CMML and one of the following high-risk features:

Poor or Very poor cytogenetic risk group as per IPSS-R
Mutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN1) or DNMT 3a or ASXL1 or RUNX1
Maximum IPSS-R >3.5 between diagnosis and the start of the preparative regimen.
≥ 5% BM blasts at transplant
Therapy-related MDS
HLA-identical sibling or a minimum of 8/8 matched unrelated donor
Participants must voluntarily sign an informed consent
Female participants of childbearing potential must have negative results for pregnancy test

Adequate hepatic and renal function per local laboratory reference range as follows:

Aspartate transaminase (AST) and alanine transaminase (ALT) < 3.0X ULN
Bilirubin <1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
Participants must have adequate renal function as demonstrated by a creatinine clearance ≥ 50 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.

Exclusion criteria:

Participants is known to be positive for HIV.
Participants has cognitive impairments and/or is a prisoner.
Participants has acute promyelocytic leukemia
Participants has known active CNS involvement with AML.

Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: participants with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
Cardiac history of CHF requiring treatment or Ejection Fraction < 50% or unstable angina;
Corrected DLCO < 65% or FEV1 < 65%;

Administration or consumption of any of the following within 3 days prior to the first dose of study drug:

grapefruit or grapefruit products
Seville oranges (including marmalade containing Seville oranges)
star fruit
Prior gemtuzumab ozogamicin and/or inotuzumab ozogamicin use
Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

103

Study ID:

NCT04708054

Recruitment Status:

Active, not recruiting

Sponsor:

M.D. Anderson Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

M D Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

103

Study ID:

NCT04708054

Recruitment Status:

Active, not recruiting

Sponsor:


M.D. Anderson Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.